The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5-6, 2024 ( http://www.cvot.org ).

3rd Medical Department and Laboratory for Endocrinology and Metabolism 1st Faculty of Medicine Charles University Prague Czech Republic

Amsterdam University Medical Centers Amsterdam The Netherlands

Biomea Fusion Redwood City CA United States of America

Center for Diabetes Education EDC Charlotte NC United States of America

Center Internal Medicine Fünf Höfe Munich Germany

Clalit Health Services Haifa Israel

Clinic for Cardiology Pneumology Angiology and Internal Intensive Care Medicine RWTH Aachen University Hospital Aachen Germany

Clinic for Endocrinology Diabetes and Metabolic Diseases University Clinical Center of Serbia Belgrade Serbia

CRS Clinical Research Services Mannheim GmbH Mannheim Germany

Department of Cardiovascular Disease Saint Luke's Mid America Heart Institute University of Missouri Kansas City School of Medicine Kansas City MO United States of America

Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen University of Groningen Groningen The Netherlands

Department of Clinical Sciences Malmö Lund University Lund Sweden

Department of Diabetes Central Medical School Monash University Melbourne Australia

Department of Endocrinology Catholic University Leuven Leuven Belgium

Department of Family Medicine Acıbadem Mehmet Ali Aydınlar University School of Medicine Istanbul Türkiye

Department of Hepatology and Gastroenterology Charité Universitätsmedizin Berlin Campus Virchow Klinikum and Campus Charité Mitte Berlin Germany

Department of Medicine K2 Karolinska Institute Stockholm Sweden

Department of Nephrology University of Helsinki and Helsinki University Hospital Helsinki Finland

Department of Pediatrics Skåne University Hospital Malmö Lund Sweden

Department of Precision and Regenerative Medicine and Ionian Area University of Bari Aldo Moro Bari Italy

Diabetes Leadership Council Indianapolis IN United States of America

Diabetes Patient Advocacy Coalition Tampa FL United States of America

Division Diabetic Complications Institute for Diabetes and Cancer Helmholtz Center Munich Neuherberg Germany

Division of Endocrinology Department of Internal Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China

Division of Nephrology and Hypertension University Hospital Fundación Jiménez Díaz Madrid Spain

Emory University School of Medicine Atlanta GA United States of America

Endocrine and Metabolic Consultants Rockville MD United States of America

Faculty of Medicine University of Belgrade Belgrade Serbia

Faculty of Medicine University of Ljubljana Ljubljana Slovenia

Forschergruppe Diabetes e 5 Helmholtz Center Munich Ingolstaedter Landstraße 1 85764 Neuherberg Germany

Future Evidence Foundation Melbourne Australia

Institute for Diabetes and Obesity Helmholtz Munich Munich Germany

IRCCS MultiMedica Milan Italy

Medical Clinic 3 University Hospital Carl Gustav Carus Dresden Germany

Peking University People's Hospital Xicheng District Beijing China

Practice for Prevention and Therapy and Cardio Metabolic Institute Villingen Schwenningen Germany

School of Public Health Imperial College London London United Kingdom

Sciarc GmbH Baierbrunn Germany

Sheffield Teaching Hospitals Sheffield United Kingdom

Shupyk National Healthcare University of Ukraine Kyiv Ukraine

Southern Health NHS Foundation Trust Southampton United Kingdom

Steno Diabetes Center Copenhagen Herlev Denmark

Technion Faculty of Medicine Haifa Israel

University Medical Center Ljubljana Slovenia

University of Sheffield Sheffield United Kingdom

Walther Straub Institute for Pharmacology and Toxicology Ludwig Maximilians University Munich Munich Germany

Weill Cornell Medicine Qatar Qatar Foundation Education City Ar Rayyan Doha Qatar

Zobrazit více v PubMed

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi: 10.1016/j.diabres.2021.109119. PubMed DOI PMC

Federation WO. World Obesity Atlas 2023. 2023.

Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83. doi: 10.1186/s12933-018-0728-6. PubMed DOI PMC

Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27. doi: 10.1056/NEJMoa1614362. PubMed DOI PMC

Rick Turner J. FDA’s New Guidance for Industry addressing evaluation of the safety of new drugs for improving Glycemic Control: a Case Study in Regulatory Science. Ther Innov Regul Sci. 2021;55(1):1–5. doi: 10.1007/s43441-020-00211-6. PubMed DOI

FDA. Guidance for Industry Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes - Guidance Document2008. Available from: https://www.regulations.gov/document/FDA-2008-D-0118-0029.

Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, Progress, and possibilities. Clin J Am Soc Nephrology: CJASN. 2017;12(12):2032–45. doi: 10.2215/CJN.11491116. PubMed DOI PMC

American Diabetes Association Standards of medical care in diabetes—2021. Diabetes Care. 2021;44(1):1–S232. PubMed

Wen CP, Chang CH, Tsai MK, Lee JH, Lu PJ, Tsai SP, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int. 2017;92(2):388–96. doi: 10.1016/j.kint.2017.01.030. PubMed DOI

Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(5):853–72. doi: 10.1002/ejhf.1170. PubMed DOI

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26. doi: 10.1056/NEJMoa1307684. PubMed DOI

White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35. doi: 10.1056/NEJMoa1305889. PubMed DOI

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42. doi: 10.1056/NEJMoa1501352. PubMed DOI

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular events in adults with type 2 diabetes and High Cardiovascular and renal risk: the CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69–79. doi: 10.1001/jama.2018.18269. PubMed DOI PMC

Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of Linagliptin vs glimepiride on major adverse Cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155–66. doi: 10.1001/jama.2019.13772. PubMed DOI PMC

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247–57. doi: 10.1056/NEJMoa1509225. PubMed DOI

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. doi: 10.1056/NEJMoa1607141. PubMed DOI

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. doi: 10.1056/NEJMoa1603827. PubMed DOI PMC

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly Exenatide on Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39. doi: 10.1056/NEJMoa1612917. PubMed DOI PMC

Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Sr., Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet (London England) 2018;392(10157):1519–29. doi: 10.1016/S0140-6736(18)32261-X. PubMed DOI

Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with Efpeglenatide in Type 2 diabetes. N Engl J Med. 2021;385(10):896–907. doi: 10.1056/NEJMoa2108269. PubMed DOI

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. doi: 10.1056/NEJMoa1611925. PubMed DOI

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. doi: 10.1056/NEJMoa1812389. PubMed DOI

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. doi: 10.1056/NEJMoa1504720. PubMed DOI

Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with Ertugliflozin in Type 2 diabetes. N Engl J Med. 2020;383(15):1425–35. doi: 10.1056/NEJMoa2004967. PubMed DOI

Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–39. doi: 10.1056/NEJMoa2030186. PubMed DOI

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi: 10.1056/NEJMoa1911303. PubMed DOI

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with Empagliflozin in Heart failure. N Engl J Med. 2020;383(15):1413–24. doi: 10.1056/NEJMoa2022190. PubMed DOI

Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–28. doi: 10.1056/NEJMoa2030183. PubMed DOI

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61. doi: 10.1056/NEJMoa2107038. PubMed DOI

Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98. doi: 10.1056/NEJMoa2206286. PubMed DOI

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306. doi: 10.1056/NEJMoa1811744. PubMed DOI

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. doi: 10.1056/NEJMoa2024816. PubMed DOI

Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–27. doi: 10.1056/NEJMoa2204233. PubMed DOI PMC

Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–63. doi: 10.1056/NEJMoa2110956. PubMed DOI

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on chronic kidney Disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–29. doi: 10.1056/NEJMoa2025845. PubMed DOI

Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, et al. Finerenone and Heart failure outcomes by kidney Function/Albuminuria in chronic kidney disease and diabetes. JACC Heart Fail. 2022;10(11):860–70. doi: 10.1016/j.jchf.2022.07.013. PubMed DOI

James S, Erlinge D, Storey RF, McGuire DK, Belder Md, Eriksson N, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 2024;3:EVIDoa2300286. PubMed

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi: 10.1056/NEJMoa2032183. PubMed DOI

Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London England) 2021;397(10278):971–84. doi: 10.1016/S0140-6736(21)00213-0. PubMed DOI

Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of Subcutaneous Semaglutide vs Placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403–13. doi: 10.1001/jama.2021.1831. PubMed DOI PMC

Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued Weekly Subcutaneous Semaglutide vs Placebo on Weight loss maintenance in adults with overweight or obesity: the STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–25. doi: 10.1001/jama.2021.3224. PubMed DOI PMC

Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (London England) 2021;398(10295):143–55. doi: 10.1016/S0140-6736(21)01324-6. PubMed DOI

Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide once Weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15. doi: 10.1056/NEJMoa2107519. PubMed DOI

Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet (London England) 2021;398(10300):583–98. doi: 10.1016/S0140-6736(21)01443-4. PubMed DOI

Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet (London England) 2021;398(10313):1811–24. doi: 10.1016/S0140-6736(21)02188-7. PubMed DOI

Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of Subcutaneous Tirzepatide vs Placebo added to titrated insulin glargine on Glycemic Control in patients with type 2 diabetes: the SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534–45. doi: 10.1001/jama.2022.0078. PubMed DOI PMC

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once Weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16. doi: 10.1056/NEJMoa2206038. PubMed DOI

Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32. doi: 10.1056/NEJMoa2307563. PubMed DOI

Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–84. doi: 10.1056/NEJMoa2306963. PubMed DOI

Vekic J, Stefanovic A, Zeljkovic A. Obesity and dyslipidemia: a review of current evidence. Curr Obes Rep. 2023;12(3):207–22. doi: 10.1007/s13679-023-00518-z. PubMed DOI

Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (London England) 2015;385(9976):1397–405. doi: 10.1016/S0140-6736(14)61368-4. PubMed DOI

Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-european Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22. doi: 10.1093/eurheartj/ehv043. PubMed DOI PMC

Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457. doi: 10.1038/ncomms13457. PubMed DOI PMC

Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic Acid and Cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–64. doi: 10.1056/NEJMoa2215024. PubMed DOI

Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2016;15:33. doi: 10.1186/s12933-016-0357-x. PubMed DOI PMC

Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2017;16(1):35. doi: 10.1186/s12933-017-0508-8. PubMed DOI PMC

Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Lalic K, et al. Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2018;17(1):30. doi: 10.1186/s12933-018-0667-2. PubMed DOI PMC

Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, et al. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2019;18(1):30. doi: 10.1186/s12933-019-0822-4. PubMed DOI PMC

Schnell O, Standl E, Cos X, Heerspink HJ, Itzhak B, Lalic N, et al. Report from the 5th cardiovascular outcome trial (CVOT) summit. Cardiovasc Diabetol. 2020;19(1):47. doi: 10.1186/s12933-020-01022-7. PubMed DOI PMC

Schnell O, Cos X, Cosentino F, Forst T, Giorgino F, Heersprink HJL, et al. Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. Cardiovasc Diabetol. 2021;20(1):75. doi: 10.1186/s12933-021-01254-1. PubMed DOI PMC

Schnell O, Battelino T, Bergenstal R, Blüher M, Böhm M, Brosius F, et al. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovasc Diabetol. 2022;21(1):50. doi: 10.1186/s12933-022-01481-0. PubMed DOI PMC

Schnell O, Battelino T, Bergenstal R, Birkenfeld AL, Ceriello A, Cheng A, et al. CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. Cardiovasc Diabetol. 2023;22(1):59. doi: 10.1186/s12933-023-01788-6. PubMed DOI PMC

Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2011;33(2):176–82. doi: 10.1093/eurheartj/ehr352. PubMed DOI

Ceriello A, Rodbard HW, Battelino T, Brosius F, Cosentino F, Green J, et al. Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop. Cardiovasc Diabetol. 2023;22(1):277. doi: 10.1186/s12933-023-01993-3. PubMed DOI PMC

Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydén L, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ (Clinical Res ed) 2023;381:e074068. PubMed PMC

Elliott J, Lawrence R, Minx JC, Oladapo OT, Ravaud P, Tendal Jeppesen B, et al. Decision makers need constantly updated evidence synthesis. Nature. 2021;600(7889):383–5. doi: 10.1038/d41586-021-03690-1. PubMed DOI

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–39. doi: 10.1093/eurheartj/ehad195. PubMed DOI

Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–140. doi: 10.1093/eurheartj/ehad192. PubMed DOI

Kunutsor SK, Khunti K, Seidu S. Racithnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials. J R Soc Med. 2023:1410768231198442. PubMed PMC

Kelly RC, Holt RIG, Desborough L, Majidi S, Town M, Naranjo D et al. The psychosocial burdens of living with diabetes. Diabet Medicine: J Br Diabet Association. 2023:e15219. PubMed

Federation ID. IDF Annual Report 2022. 2022.

Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011) 2022;12(1):7–11. doi: 10.1016/j.kisu.2021.11.003. PubMed DOI PMC

Collaboration GCKD. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet (London England) 2020;395(10225):709–33. doi: 10.1016/S0140-6736(20)30045-3. PubMed DOI PMC

de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a Consensus Report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO) Diabetes Care. 2022;45(12):3075–90. doi: 10.2337/dci22-0027. PubMed DOI PMC

Seidu S, Cos X, Topsever P. Self-rated knowledge and competence regarding the management of chronic kidney disease in primary care: a cross-sectional European survey of primary care professionals. Prim Care Diabetes. 2023;17(1):19–26. doi: 10.1016/j.pcd.2022.11.013. PubMed DOI

Schultes B, Emmerich S, Kistler AD, Mecheri B, Schnell O, Rudofsky G. Impact of albumin-to-creatinine ratio point-of-care testing on the diagnosis and management of Diabetic kidney disease. J Diabetes Sci Technol. 2023;17(2):428–38. doi: 10.1177/19322968211054520. PubMed DOI PMC

Nephrology ISo. Chronic Kidney Disease (CKD) Early Identification and Intervention in Primary Care. 2023.

Group KDIGOKDW. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in chronic kidney disease. Kidney Int. 2022;102(5s):1–s127. PubMed

von Scholten BJ, Kreiner FF, Rasmussen S, Rossing P, Idorn T. The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice. Ther Adv Endocrinol Metab. 2022;13:20420188221112490. PubMed PMC

Consortium, NDoPHRSGSiM-AC-RT Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet (London England) 2022;400(10365):1788–801. doi: 10.1016/S0140-6736(22)02074-8. PubMed DOI PMC

Heerspink HJL, Kiyosue A, Wheeler DC, Lin M, Wijkmark E, Carlson G, et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet (London England) 2023;402(10416):2004–17. doi: 10.1016/S0140-6736(23)02230-4. PubMed DOI

Bakris GL, Yang YF, McCabe JM, Liu JR, Tan XJ, Benn VJ, et al. Efficacy and safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study. Am J Hypertens. 2023;36(11):612–8. doi: 10.1093/ajh/hpad066. PubMed DOI PMC

Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, et al. Outcomes with Finerenone in participants with stage 4 CKD and type 2 diabetes: a FIDELITY Subgroup Analysis. Clin J Am Soc Nephrology: CJASN. 2023;18(5):602–12. doi: 10.2215/CJN.0000000000000149. PubMed DOI PMC

Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018;6(6):e6–e15. doi: 10.1016/S2213-8587(18)30150-5. PubMed DOI PMC

Collaborators GCRF. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the global burden of Disease Study 2019. Lancet (London England) 2022;400(10352):563–91. doi: 10.1016/S0140-6736(22)01438-6. PubMed DOI PMC

Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97. doi: 10.1038/nri2921. PubMed DOI PMC

Rios Garcia M, Steinbauer B, Srivastava K, Singhal M, Mattijssen F, Maida A, et al. Acetyl-CoA carboxylase 1-Dependent protein acetylation controls breast Cancer metastasis and recurrence. Cell Metab. 2017;26(6):842–55e5. doi: 10.1016/j.cmet.2017.09.018. PubMed DOI

Zhang AMY, Xia YH, Lin JSH, Chu KH, Wang WCK, Ruiter TJJ, et al. Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammation. Cell Metabol. 2023;35(12):2119–35e5. doi: 10.1016/j.cmet.2023.10.003. PubMed DOI

Chettouh H, Lequoy M, Fartoux L, Vigouroux C, Desbois-Mouthon C. Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma. Liver Int. 2015;35(10):2203–17. doi: 10.1111/liv.12903. PubMed DOI

Tacke F, Puengel T, Loomba R, Friedman SL. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol. 2023;79(2):552–66. doi: 10.1016/j.jhep.2023.03.038. PubMed DOI

Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497–509. doi: 10.1056/NEJMoa2309000. PubMed DOI

Harrison SA, Ruane PJ, Freilich B, Neff G, Patil R, Behling C, et al. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Rep. 2023;5(1):100563. doi: 10.1016/j.jhepr.2022.100563. PubMed DOI PMC

Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al. Randomized, controlled trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med. 2023;389(11):998–1008. doi: 10.1056/NEJMoa2304286. PubMed DOI PMC

Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511–22. doi: 10.1016/S2468-1253(23)00068-7. PubMed DOI PMC

A study of tirzepatide (LY3298176). in participants with nonalcoholic steatohepatitis (NASH) (SYNERGY-NASH) [Internet]. 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT04166773.

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–56. doi: 10.1016/j.jhep.2023.06.003. PubMed DOI

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29(1):101133. doi: 10.1016/j.aohep.2023.101133. PubMed DOI

Zhang Q, Delessa CT, Augustin R, Bakhti M, Colldén G, Drucker DJ, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 2021;33(4):833–44e5. doi: 10.1016/j.cmet.2021.01.015. PubMed DOI PMC

Liskiewicz A, Khalil A, Liskiewicz D, Novikoff A, Grandl G, Maity-Kumar G, et al. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice. Nat Metab. 2023;5(12):2075–85. doi: 10.1038/s42255-023-00931-7. PubMed DOI PMC

Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschöp MH. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010;6(12):689–97. doi: 10.1038/nrendo.2010.187. PubMed DOI PMC

Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London England) 2023;402(10401):529–44. doi: 10.1016/S0140-6736(23)01053-X. PubMed DOI

Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–26. doi: 10.1056/NEJMoa2301972. PubMed DOI

Aroda VR, Aberle J, Bardtrum L, Christiansen E, Knop FK, Gabery S, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet (London England) 2023;402(10403):693–704. doi: 10.1016/S0140-6736(23)01127-3. PubMed DOI

Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet (London England) 2023;402(10400):472–83. doi: 10.1016/S0140-6736(23)01302-8. PubMed DOI

Schabert J, Browne JL, Mosely K, Speight J. Social stigma in diabetes: a framework to understand a growing problem for an increasing epidemic. Patient. 2013;6(1):1–10. doi: 10.1007/s40271-012-0001-0. PubMed DOI

Nutter S, Eggerichs LA, Nagpal TS, Ramos Salas X, Chin Chea C, Saiful S, et al. Changing the global obesity narrative to recognize and reduce weight stigma: a position statement from the World Obesity Federation. Obes Rev. 2024;25(1):e13642. doi: 10.1111/obr.13642. PubMed DOI

Albury C, Webb H, Stokoe E, Ziebland S, Koshiaris C, Lee JJ, et al. Relationship between Clinician Language and the success of behavioral weight loss interventions: a mixed-methods cohort study. Ann Intern Med. 2023;176(11):1437–47. doi: 10.7326/M22-2360. PubMed DOI

Ogle GD, Wang F, Gregory GA, Maniam J. Type 1 diabetes mellitus estimates in children and adults. Brussels, Belgium: International Diabetes Federation; 2022.

Gregory GA, Robinson TIG, Linklater SE, Wang F, Colagiuri S, de Beaufort C, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741–60. doi: 10.1016/S2213-8587(22)00218-2. PubMed DOI

Quinn LM, Wong FS, Narendran P. Environmental determinants of type 1 diabetes: from Association to proving causality. Front Immunol. 2021;12:737964. doi: 10.3389/fimmu.2021.737964. PubMed DOI PMC

Hummel S, Carl J, Friedl N, Winkler C, Kick K, Stock J, et al. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia. 2023;66(9):1633–42. doi: 10.1007/s00125-023-05953-0. PubMed DOI PMC

Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13:583. doi: 10.1126/scitranslmed.abc8980. PubMed DOI PMC

Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, et al. Teplizumab and β-Cell function in newly diagnosed type 1 diabetes. N Engl J Med. 2023;389(23):2151–61. doi: 10.1056/NEJMoa2308743. PubMed DOI

Elliott J, Sloan G, Stevens L, Selvarajah D, Cruccu G, Gandhi RA, et al. Female sex is a risk factor for painful diabetic peripheral neuropathy: the EURODIAB prospective diabetes complications study. Diabetologia. 2024;67(1):190–8. doi: 10.1007/s00125-023-06025-z. PubMed DOI PMC

Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Julious S, et al. Comparison of Amitriptyline supplemented with Pregabalin, Pregabalin supplemented with Amitriptyline, and duloxetine supplemented with Pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet (London England) 2022;400(10353):680–90. doi: 10.1016/S0140-6736(22)01472-6. PubMed DOI PMC

Ziegler D, Tesfaye S, Spallone V, Gurieva I, Al Kaabi J, Mankovsky B, et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Res Clin Pract. 2022;186:109063. doi: 10.1016/j.diabres.2021.109063. PubMed DOI

El-Nahas MR, Elkannishy G, Abdelhafez H, Elkhamisy ET, El-Sehrawy AA. Oral alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: a Randomized double-blinded placebo-controlled study. Endocr Metab Immune Disord Drug Targets. 2020;20(9):1531–4. doi: 10.2174/1871530320666200506081407. PubMed DOI

Nguyen N, Takemoto JK. A case for alpha-lipoic acid as an Alternative Treatment for Diabetic Polyneuropathy. J Pharm Pharm Sci. 2018;21(1s):177s–91s. doi: 10.18433/jpps30100. PubMed DOI

Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34(9):2054–60. doi: 10.2337/dc11-0503. PubMed DOI PMC

Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Experimental and clinical endocrinology & diabetes: official journal. German Soc Endocrinol [and] German Diabetes Association. 2008;116(10):600–5. doi: 10.1055/s-2008-1065351. PubMed DOI

Celis-Morales CA, Franzén S, Eeg-Olofsson K, Nauclér E, Svensson AM, Gudbjornsdottir S, et al. Type 2 diabetes, Glycemic Control, and their Association with Dementia and its major subtypes: findings from the Swedish National Diabetes Register. Diabetes Care. 2022;45(3):634–41. doi: 10.2337/dc21-0601. PubMed DOI

Hu J, Fang M, Pike JR, Lutsey PL, Sharrett AR, Wagenknecht LE, et al. Prediabetes, intervening diabetes and subsequent risk of dementia: the atherosclerosis risk in communities (ARIC) study. Diabetologia. 2023;66(8):1442–9. doi: 10.1007/s00125-023-05930-7. PubMed DOI PMC

Sugimoto T, Tokuda H, Miura H, Kawashima S, Ando T, Kuroda Y, et al. Cross-sectional association of metrics derived from continuous glucose monitoring with cognitive performance in older adults with type 2 diabetes. Diabetes Obes Metab. 2023;25(1):222–8. doi: 10.1111/dom.14866. PubMed DOI

Li R, Geng T, Li L, Lu Q, Li R, Chen X, et al. Associations of glucose metabolism status with brain macrostructure and microstructure: findings from the UK Biobank. J Clin Endocrinol Metab. 2023;109(1):e234–e42. doi: 10.1210/clinem/dgad442. PubMed DOI

Monereo-Sánchez J, Jansen JFA, Köhler S, van Boxtel MPJ, Backes WH, Stehouwer CDA, et al. The association of prediabetes and type 2 diabetes with hippocampal subfields volume: the Maastricht study. Neuroimage Clin. 2023;39:103455. doi: 10.1016/j.nicl.2023.103455. PubMed DOI PMC

Lu J, Wang C, Shen Y, Chen L, Zhang L, Cai J, et al. Time in Range in Relation to all-cause and Cardiovascular Mortality in patients with type 2 diabetes: a prospective cohort study. Diabetes Care. 2021;44(2):549–55. doi: 10.2337/dc20-1862. PubMed DOI PMC